Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals

ABSTRACT Increases in bone mineral density (BMD) with osteoporosis treatment are associated with reduced fracture risk. Increasing BMD is therefore a goal of osteoporosis therapy. Here, we compare the probability of achieving a T‐score of > −2.5 over 3 years at the total hip (TH) or lumbar spine...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Felicia Cosman, Cesar Libanati, Cynthia Deignan, Zhigang Yu, Zhenxun Wang, Serge Ferrari, Jens‐Erik Beck Jensen, Pilar Peris, Francesco Bertoldo, Eric Lespessailles, Eric Hesse, Steven R Cummings
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	ANABOLICS ANTIRESORPTIVES CLINICAL TRIALS DXA OSTEOPOROSIS Orthopedic surgery RD701-811 Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/39be35b5ab714be384692183a32a8b87
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:39be35b5ab714be384692183a32a8b87
record_format	dspace
spelling	oai:doaj.org-article:39be35b5ab714be384692183a32a8b872021-11-04T12:00:57ZRomosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals2473-403910.1002/jbm4.10546https://doaj.org/article/39be35b5ab714be384692183a32a8b872021-11-01T00:00:00Zhttps://doi.org/10.1002/jbm4.10546https://doaj.org/toc/2473-4039ABSTRACT Increases in bone mineral density (BMD) with osteoporosis treatment are associated with reduced fracture risk. Increasing BMD is therefore a goal of osteoporosis therapy. Here, we compare the probability of achieving a T‐score of > −2.5 over 3 years at the total hip (TH) or lumbar spine (LS) in women with osteoporosis, ≥55 years of age, after the following treatment sequences: 1 year romosozumab followed by 2 years denosumab (FRAME and FRAME extension trials), 1 year romosozumab followed by 2 years alendronate, or alendronate‐only for 3 years (ARCH trial). Probabilities of attaining the BMD target within 1 year of treatment were also determined. At both skeletal sites, in women with a baseline Tscore ≥ −2.7, there was >50% probability of achieving the BMD target with any 3‐year regimen. The probability of achieving the target BMD in those with a baseline TH Tscore equal to −3.0 was 61% with romosozumab/denosumab, 38% with romosozumab/alendronate, and 9% with alendronate. In those with a baseline LS Tscore equal to −3.0, the probability of achieving a T‐score > −2.5 was 93% with romosozumab/denosumab, 81% with romosozumab/alendronate, and 55% with alendronate. With 1 year of treatment, in patients with a baseline TH T‐score equal to −2.7, the probability of reaching the target Tscore with romosozumab was 71% to 78% and 38% with alendronate. For patients with an initial LS T‐score equal to −3.0, the probability of achieving the target T‐score over 1 year was 85% to 86% with romosozumab and 25% for alendronate. Our findings suggest baseline BMD and the probability of achieving BMD T‐score goals are factors to consider when selecting initial treatment for patients with osteoporosis. As baseline T‐score falls below −2.7 (TH) and −3.0 (LS), alendronate has <50% likelihood of achieving a BMD goal above osteoporosis range, whereas these probabilities remain relatively high for regimens beginning with romosozumab. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.Felicia CosmanCesar LibanatiCynthia DeignanZhigang YuZhenxun WangSerge FerrariJens‐Erik Beck JensenPilar PerisFrancesco BertoldoEric LespessaillesEric HesseSteven R CummingsWileyarticleANABOLICSANTIRESORPTIVESCLINICAL TRIALSDXAOSTEOPOROSISOrthopedic surgeryRD701-811Diseases of the musculoskeletal systemRC925-935ENJBMR Plus, Vol 5, Iss 11, Pp n/a-n/a (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ANABOLICS ANTIRESORPTIVES CLINICAL TRIALS DXA OSTEOPOROSIS Orthopedic surgery RD701-811 Diseases of the musculoskeletal system RC925-935
spellingShingle	ANABOLICS ANTIRESORPTIVES CLINICAL TRIALS DXA OSTEOPOROSIS Orthopedic surgery RD701-811 Diseases of the musculoskeletal system RC925-935 Felicia Cosman Cesar Libanati Cynthia Deignan Zhigang Yu Zhenxun Wang Serge Ferrari Jens‐Erik Beck Jensen Pilar Peris Francesco Bertoldo Eric Lespessailles Eric Hesse Steven R Cummings Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals
description	ABSTRACT Increases in bone mineral density (BMD) with osteoporosis treatment are associated with reduced fracture risk. Increasing BMD is therefore a goal of osteoporosis therapy. Here, we compare the probability of achieving a T‐score of > −2.5 over 3 years at the total hip (TH) or lumbar spine (LS) in women with osteoporosis, ≥55 years of age, after the following treatment sequences: 1 year romosozumab followed by 2 years denosumab (FRAME and FRAME extension trials), 1 year romosozumab followed by 2 years alendronate, or alendronate‐only for 3 years (ARCH trial). Probabilities of attaining the BMD target within 1 year of treatment were also determined. At both skeletal sites, in women with a baseline Tscore ≥ −2.7, there was >50% probability of achieving the BMD target with any 3‐year regimen. The probability of achieving the target BMD in those with a baseline TH Tscore equal to −3.0 was 61% with romosozumab/denosumab, 38% with romosozumab/alendronate, and 9% with alendronate. In those with a baseline LS Tscore equal to −3.0, the probability of achieving a T‐score > −2.5 was 93% with romosozumab/denosumab, 81% with romosozumab/alendronate, and 55% with alendronate. With 1 year of treatment, in patients with a baseline TH T‐score equal to −2.7, the probability of reaching the target Tscore with romosozumab was 71% to 78% and 38% with alendronate. For patients with an initial LS T‐score equal to −3.0, the probability of achieving the target T‐score over 1 year was 85% to 86% with romosozumab and 25% for alendronate. Our findings suggest baseline BMD and the probability of achieving BMD T‐score goals are factors to consider when selecting initial treatment for patients with osteoporosis. As baseline T‐score falls below −2.7 (TH) and −3.0 (LS), alendronate has <50% likelihood of achieving a BMD goal above osteoporosis range, whereas these probabilities remain relatively high for regimens beginning with romosozumab. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
format	article
author	Felicia Cosman Cesar Libanati Cynthia Deignan Zhigang Yu Zhenxun Wang Serge Ferrari Jens‐Erik Beck Jensen Pilar Peris Francesco Bertoldo Eric Lespessailles Eric Hesse Steven R Cummings
author_facet	Felicia Cosman Cesar Libanati Cynthia Deignan Zhigang Yu Zhenxun Wang Serge Ferrari Jens‐Erik Beck Jensen Pilar Peris Francesco Bertoldo Eric Lespessailles Eric Hesse Steven R Cummings
author_sort	Felicia Cosman
title	Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals
title_short	Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals
title_full	Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals
title_fullStr	Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals
title_full_unstemmed	Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals
title_sort	romosozumab followed by antiresorptive treatment increases the probability of achieving bone mineral density treatment goals
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/39be35b5ab714be384692183a32a8b87
work_keys_str_mv	AT feliciacosman romosozumabfollowedbyantiresorptivetreatmentincreasestheprobabilityofachievingbonemineraldensitytreatmentgoals AT cesarlibanati romosozumabfollowedbyantiresorptivetreatmentincreasestheprobabilityofachievingbonemineraldensitytreatmentgoals AT cynthiadeignan romosozumabfollowedbyantiresorptivetreatmentincreasestheprobabilityofachievingbonemineraldensitytreatmentgoals AT zhigangyu romosozumabfollowedbyantiresorptivetreatmentincreasestheprobabilityofachievingbonemineraldensitytreatmentgoals AT zhenxunwang romosozumabfollowedbyantiresorptivetreatmentincreasestheprobabilityofachievingbonemineraldensitytreatmentgoals AT sergeferrari romosozumabfollowedbyantiresorptivetreatmentincreasestheprobabilityofachievingbonemineraldensitytreatmentgoals AT jenserikbeckjensen romosozumabfollowedbyantiresorptivetreatmentincreasestheprobabilityofachievingbonemineraldensitytreatmentgoals AT pilarperis romosozumabfollowedbyantiresorptivetreatmentincreasestheprobabilityofachievingbonemineraldensitytreatmentgoals AT francescobertoldo romosozumabfollowedbyantiresorptivetreatmentincreasestheprobabilityofachievingbonemineraldensitytreatmentgoals AT ericlespessailles romosozumabfollowedbyantiresorptivetreatmentincreasestheprobabilityofachievingbonemineraldensitytreatmentgoals AT erichesse romosozumabfollowedbyantiresorptivetreatmentincreasestheprobabilityofachievingbonemineraldensitytreatmentgoals AT stevenrcummings romosozumabfollowedbyantiresorptivetreatmentincreasestheprobabilityofachievingbonemineraldensitytreatmentgoals
_version_	1718444892256993280

Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals

Ejemplares similares